Trial: A Study of Disitamab Vedotin With Other…

Trial Details

Sponsor: Seagen, a wholly owned subsidiary of Pfizer (industry)

Phase: 2

Start date: May 20, 2024

Planned enrollment: 172

Trial ID: NCT06157892

More trial details at ClinicalTrials.gov

Show Summary from Sponsor

This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to treat. This is called advanced or metastatic cancer. Participants in this study must have breast cancer or gastric cancer. Participants must have tumors that have HER2 on them. This allows the cancer to grow more quickly or spread faster. There are few treatment options for patients with advanced or metastatic solid tumors that express HER2. This clinical trial uses an experimental drug called disitamab vedotin (DV). Disitamab vedotin is a type of antibody drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. This clinical trial uses a drug called tucatinib, which has been approved to treat cancer in the United States and some other countries. This drug is sold under the brand name TUKYSA®. This study will test how safe and how well DV with tucatinib works for participants with solid tumors. This study will also test what side effects happen when participants take these drugs. A side effect is anything a drug does to the body besides treating the disease.

More details:

This clinical trial is to evaluate disitamab vedotin in combination with tucatinib in subjects with LA/metastatic breast cancer or gastric cancer/GEJC that express HER2. The study has a dose escalation phase evaluating disitamab vedotin plus tucatinib followed by a dose optimization phase. The 2 dose levels identified in the dose escalation phase will be assessed in the optimization phase for both safety and efficacy in HER2-expressing LA/mBC and LA/mGC/GEJC. Once the safety and efficacy profile of disitamab vedotin plus tucatinib has been established and a disitamab vedotin dose with the optimum benefit/risk ratio has been determined the disitamab vedotin plus tucatinib combination therapy will be evaluated in an expansion phase with 4 expansion cohorts in subjects with HER2-low LA/mGC/GEJC, HER2+ LA/mGC/GEJC, HER2-low LA/mBC, and HER2+ LA/mBC.

Investigational Drug AI Analysis

Show for: disitamab vedotin (RC48, Aidixi)

Disitamab vedotin (RC48, Aidixi) is an antibody-drug conjugate (ADC) that targets HER2-expressing cancers. It consists of a humanized anti-HER2 monoclonal antibody (disitamab) conjugated to the cytotoxic agent monomethyl auristatin E (MMAE) via a cleavable vedotin linker [1]. The drug works through multiple mechanisms including direct cytotoxicity to HER2-expressing cells, bystander effect on neighboring cells, immunogenic cell death, and inhibition of HER2 signaling pathways. It received its first approval in China in June 2021 for HER2-overexpressing locally advanced or metastatic gastric cancer after at least two lines of chemotherapy [2].

Clinical Efficacy and Safety

Clinical trials have shown promising results across multiple cancer types. In HER2-expressing metastatic breast cancer, the drug demonstrated objective response rates of 42.9% in HER2-overexpressing and 33.3% in HER2-low disease, with median progression-free survival of 5.7 and 5.1 months respectively [3]. In urothelial carcinoma, when combined with the immunotherapy drug toripalimab, it showed a 73.2% response rate with median progression-free survival of 9.2 months [4]. Common adverse events include elevated liver enzymes, peripheral neuropathy, asthenia, and neutropenia. Grade 3 or higher adverse events occurred in about 40-44% of patients across trials, but were generally manageable.

The drug is currently being investigated in multiple ongoing clinical trials, including phase 3 studies in various cancers. It is being studied both as monotherapy and in combination with other agents like immunotherapy drugs and targeted therapies. Development is focused on both HER2-overexpressing and HER2-low expressing cancers, with studies ongoing in breast cancer, gastric cancer, urothelial cancer, and other solid tumors.

Sources:

[1] AACR Abstract on Mechanism of Action [2] Review Article on Development and Approval [3] Phase I/Ib Study in Breast Cancer [4] Phase 1b/2 Study in Urothelial Cancer

Last updated: Dec 2024

HealthScout AI Analysis

Goal: The trial aims to assess the safety, tolerability, and preliminary efficacy of disitamab vedotin in combination with tucatinib in patients with locally advanced or metastatic HER2-expressing breast cancer or gastric/gastroesophageal junction adenocarcinoma. The study will determine optimal dosing and evaluate the benefit/risk profile of this combination across HER2-low and HER2-positive disease settings.

Patients: Eligible patients have locally advanced or metastatic breast cancer or gastric/gastroesophageal junction adenocarcinoma with measurable disease and HER2 expression (either HER2-low or HER2-positive), ECOG 0-1, and must have received and progressed on or been intolerant to standard therapies. Four main cohorts will be studied based on cancer type (breast or gastric/GEJC) and HER2 status (low or positive).

Design: The trial uses an open-label, randomized, multi-phase design. Initial dose escalation and optimization phases inform combination tolerability and identify appropriate dosing, followed by a dose expansion phase with four specific HER2-low and HER2+ patient cohorts. Approximately 172 patients will be enrolled.

Treatments: All patients receive the combination of disitamab vedotin and tucatinib. Disitamab vedotin is an antibody-drug conjugate targeting HER2, composed of a humanized anti-HER2 monoclonal antibody linked to the cytotoxic agent MMAE. In clinical trials, it has demonstrated promising ORR and PFS in both HER2-high and HER2-low metastatic breast cancer and is approved in China for metastatic gastric cancer after chemotherapy. Common adverse events include elevated liver enzymes, neuropathy, asthenia, and neutropenia, with grade 3+ AEs manageable in most patients. Tucatinib is an approved small molecule HER2 tyrosine kinase inhibitor marketed as TUKYSA and is included in the regimen for its efficacy in HER2-positive disease.

Outcomes: Primary endpoints include safety measures (rates of laboratory abnormalities, dose-limiting toxicities, adverse events, and dose modifications) and efficacy (objective response rate per RECIST v1.1). Secondary endpoints include duration of response, disease control rate, progression-free survival, overall survival, pharmacokinetics, and immunogenicity (ADA incidence).

Burden on patient: The patient burden is moderate to high, particularly in the dose escalation phase. Participants will undergo frequent clinic visits for safety assessments, adverse event monitoring, laboratory testing, pharmacokinetic blood draws, and imaging for disease assessment. Additional tumor biopsies may be required for HER2 status confirmation, and patients with gastric/GEJ cancer must provide archival or repeat tumor tissue. Such intensive monitoring and testing exceed standard of care and are typical for early phase combination studies.

Eligibility

Show Criteria

Inclusion Criteria:

General Inclusion Criteria

* Measurable disease according to RECIST v1.1

* Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1

Dose Escalation and Optimization Phase Inclusion Criteria

* Histologically or cytologically confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma or breast carcinoma

* Locally-advanced, unresectable, or metastatic stage

* Must have experienced disease progression on or after standard of care therapies or be intolerant of standard of care therapies.

Cohort A (HER2-Low Breast Cancer) Inclusion Criteria

* Histologically or cytologically confirmed diagnosis of breast carcinoma

* Locally-advanced, unresectable, or metastatic stage

* HER2-low status determined by most recent local assessment (IHC 1+ or IHC 2+/ISH-negative)

* Prior therapies requirements

* No more than 3 prior systemic cytotoxic chemotherapy regimens (including ADCs) for LA/mBC.

* Participants with known BRCA mutation must have received a PARP-inhibitor where available and not medically contraindicated

* Have progression on or after, or intolerant to, T-DXd, sacituzumab govitecan, or other topoisomerase I inhibitor therapies, if available as local standard of care therapy

* Participants with HR+ tumors must have intolerance to endocrine therapy or endocrine therapy refractory disease:

* Progressed on ≥2 lines of endocrine therapy for LA/mBC AND had received a CDK4/6 inhibitor in the adjuvant or metastatic setting OR

* Progressed on 1 line of endocrine therapy for LA/mBC AND had a relapse while on adjuvant endocrine therapy after definitive surgery for primary tumor AND had received a CDK4/6 inhibitor in the adjuvant or advanced setting

* Participants with HR negative, HER2-low and PD-L1-positive (CPS 10 or greater) tumors must have received pembrolizumab with chemotherapy if available as local standard of care therapy.

* Participants with HR negative, HER2-low and PD-L1-positive (CPS 10 or greater) tumors must have received pembrolizumab (or other PD-(L)1 inhibitor) with chemotherapy if available as local standard of care therapy and not medically contraindicated.

Cohort B (HER2+ Breast Cancer) Inclusion Criteria

* Histologically or cytologically confirmed diagnosis breast carcinoma

* Locally-advanced, unresectable, or metastatic stage

* HER2+ status determined by most recent local assessment (IHC 3+ or IHC 2+/ISH+)

* Participants must have:

* Received prior trastuzumab, pertuzumab and a taxane if available as local standard of care therapy for advanced disease.

* Have progression on or after, or intolerant to, T-DXd or other topoisomerase I inhibitor therapies

* No more than 3 prior systemic cytotoxic chemotherapy regimens (including ADCs) for LA/mBC

Cohort C (HER2-Low Gastric or Gastroesophageal Junction Adenocarcinoma) Inclusion Criteria

* Histologically or cytologically confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma

* Locally-advanced, unresectable, or metastatic stage

* HER2-low expression defined as IHC 1+ or IHC 2+/ISH-negative determined by most recent local assessment

* Willing and able to provide archival or newly obtained formalin-fixed paraffin-embedded (FFPE) tumor tissue blocks

* Participants must have received:

* Prior systemic therapy with platinum, fluorouracil, or taxane for locally advanced unresectable or metastatic disease

* Progression within 6 months of last dose of (neo)adjuvant cytotoxic chemotherapy is considered as 1 line of systemic therapy for LA/mGC/GEJC

* Prior anti-PD-(L)1 therapy is allowed

* No more than 2 prior systemic cytotoxic chemotherapy regimens (including ADC) for LA/mGC/GEJC

* Must not have received prior treatment with HER2 directed therapy

Cohort D (HER2+ LA/mGC/GEJC) Inclusion Criteria

* Histologically or cytologically confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma

* Locally-advanced, unresectable, or metastatic stage

* HER2+ status determined by most recent local assessment (IHC 3+ or IHC 2+/ISH+)

* Participants must have:

* Received prior trastuzumab plus fluoropyrimidine and platinum containing chemotherapy if no contraindication.

* Prior T-DXd treatment is allowed

* Prior PD1 inhibitor therapy is allowed

* No more than 2 prior systemic cytotoxic chemotherapy regimens (including ADCs) for LA/mGC/GEJC

Exclusion Criteria:

* Known hypersensitivity to any excipient contained in the drug formulation of disitamab vedotin or tucatinib

* Prior therapy with ADCs with MMAE payload

* Prior therapy with tucatinib

* Active CNS and/or leptomeningeal metastasis.

* Participants who have received prior systemic anticancer treatment including investigational agents within 4 weeks prior to first dose of study treatment

* History of other invasive malignancy within 3 years before the first dose of study intervention, or any evidence of residual disease from a previously diagnosed malignancy.

* Unable to swallow oral tablets or capsules or any significant GI disease which would preclude the adequate oral absorption of medications

Sites (123)

Sort by distance to:

Slade Health

Mount Waverley, Victoria, 3149, Australia

No email / No phone

Status: Not yet recruiting

Slade Pharmacy Frankston

Frankston, Victoria, 3199, Australia

No email / No phone

Status: Not yet recruiting

Peninsula & South Eastern Hematology and Oncology Group (PASO)

Frankston, Victoria, 3199, Australia

No email / No phone

Status: Not yet recruiting

Peninsula & South Eastern Hematology and Oncology Group (PASO)

Frankston, Australia

No email / No phone

Status: Not yet recruiting

BC Cancer Kelowna.

Kelowna, British Columbia, V1Y5L3, Canada

No email / No phone

Status: Recruiting

University Health Network, Princess Margaret Hospital

Toronto, Ontario, M5G 2M9, Canada

No email / No phone

Status: Recruiting

Ottawa Hospital Cancer Centre

Ottawa, Ontario, K1H 8L6, Canada

No email / No phone

Status: Recruiting

Sunnybrook Health Sciences Centre

Toronto, Ontario, M4N 3M5, Canada

No email / No phone

Status: Recruiting

Universitatsklinikum Essen

Essen, 45147, Germany

No email / No phone

Status: Not yet recruiting

Universitatsklinikum Heidelberg

Heidelberg, 69120, Germany

No email / No phone

Status: Not yet recruiting

Klinikums rechts der Isar der TU München

Muenchen, 81675, Germany

No email / No phone

Status: Not yet recruiting

A.O.U. Federico II

Napoli, Campania, 80131, Italy

No email / No phone

Status: Not yet recruiting

Azienda Ospedaliera Universitaria (AOU) Federico II

Napoli, Campania, 80131, Italy

No email / No phone

Status: Not yet recruiting

Istituto Nazionale Tumori IRCCS Fondazione G. Pascale.

Napoli, Campania, 80131, Italy

No email / No phone

Status: Not yet recruiting

Istituto Europeo di Oncologia

Milano, Lombardia, 20141, Italy

No email / No phone

Status: Not yet recruiting

Niguarda Ca' Granda Hospital

Milano, Lombardia, 20162, Italy

No email / No phone

Status: Not yet recruiting

Humanitas Istituto Clinico Catanese

Misterbianco (CT), Sicilia, 95045, Italy

No email / No phone

Status: Not yet recruiting

Azienda Ospedaliera Universitaria Integrata di Verona.

Verona, Veneto, 37134, Italy

No email / No phone

Status: Not yet recruiting

A.O.U. Federico II- U.O.C. Diagnostica per lmmagini e Radioterapia

Napoli, 80131, Italy

No email / No phone

Status: Not yet recruiting

Dong-A University Hospital

Busan, Other, 49201, Korea, Republic of

No email / No phone

Status: Not yet recruiting

National Cancer Center

Goyang-si, Other, 10408, Korea, Republic of

No email / No phone

Status: Not yet recruiting

Chungbuk National University Hospital

Cheongju-si, 28644, Korea, Republic of

No email / No phone

Status: Not yet recruiting

Gachon University Gil Medical Center

Incheon, 21565, Korea, Republic of

No email / No phone

Status: Not yet recruiting

Seoul National University Bundang Hospital

Seongnam-si, 463-707, Korea, Republic of

No email / No phone

Status: Not yet recruiting

Korea University Anam Hospital

Seoul, 02841, Korea, Republic of

No email / No phone

Status: Not yet recruiting

Samsung Medical Center

Seoul, 06351, Korea, Republic of

No email / No phone

Status: Not yet recruiting

Seoul National University Hospital

Seoul, 110-744, Korea, Republic of

No email / No phone

Status: Not yet recruiting

Severance Hospital Yonsei University Health System

Seoul, 3722, Korea, Republic of

No email / No phone

Status: Not yet recruiting

St. Vincent's Hospital, The Catholic University of Korea

Suwon-si, 16247, Korea, Republic of

No email / No phone

Status: Not yet recruiting

Quirén Salud Barcelona

Barcelona, 08023, Spain

No email / No phone

Status: Recruiting

Hospital Clinico Universitario de Valencia

Valencia, 46010, Spain

No email / No phone

Status: Recruiting

Ecg Medica Sl

Valencia, 46004, Spain

No email / No phone

Status: Recruiting

START Madrid-CIOCC_Hospital HM Sanchinarro

Madrid, 28050, Spain

No email / No phone

Status: Recruiting

Farmacia-Ensayos. Planta S - Hospital Universitario HM Sanchinarro-CIOCC-START Madrid

Madrid, 28050, Spain

No email / No phone

Status: Recruiting

L'Institut Catala d'Oncologia.

L'Hospitalet de Llobregat, 08908, Spain

No email / No phone

Status: Recruiting

Grupo Hospitalario QuironSalud

Erandio Bizkaia, 48950, Spain

No email / No phone

Status: Not yet recruiting

Hospital Universitario de Basurto

Bilbao, 48013, Spain

No email / No phone

Status: Not yet recruiting

CETIR Grup Medic

Barcelona, 08950, Spain

No email / No phone

Status: Recruiting

Hospital Universitari Vall d´Hebron

Barcelona, 08035, Spain

No email / No phone

Status: Recruiting

National Cheng Kung University Hospital

Tainan, 704, Taiwan

No email / No phone

Status: Not yet recruiting

National Taiwan University Hospital

Taipei, 100225, Taiwan

No email / No phone

Status: Not yet recruiting

National Taiwan University Hospital

Taipei, 100, Taiwan

No email / No phone

Status: Not yet recruiting

National Taiwan University Cancer Center

Taipei, 106, Taiwan

No email / No phone

Status: Not yet recruiting

National Cheng Kung University Hospital

Tainan, 704017, Taiwan

No email / No phone

Status: Not yet recruiting

The Royal Marsden Hospital

Sutton, Surrey, SM2 5PT, United Kingdom

No email / No phone

Status: Recruiting

The Royal Marsden NHS Foundation Trust

Sutton, SM2 5PT, United Kingdom

No email / No phone

Status: Not yet recruiting

St Bartholomew's Hospital

London, EC1M 6BQ, United Kingdom

No email / No phone

Status: Not yet recruiting

The Royal Marsden Hospital

London, SW3 6JJ, United Kingdom

No email / No phone

Status: Recruiting

The Royal Marsden NHS Foundation Trust (RM)

London, SW3 6JJ, United Kingdom

No email / No phone

Status: Recruiting

The Christie NHS Foundation Trust

Manchester, M20 4GJ, United Kingdom

No email / No phone

Status: Not yet recruiting

The University of Arizona Cancer Center-Main

Tucson, Arizona, 85724, United States

No email / No phone

Status: Recruiting

University of Arizona Cancer Center - North Campus

Tucson, Arizona, 85719, United States

No email / No phone

Status: Recruiting

The University of Arizona Cancer Center-North Campus Pharmacy, Attn: Kelly Myrdal

Tucson, Arizona, 85719, United States

No email / No phone

Status: Recruiting

Banner-University Medical Center Tucson

Tucson, Arizona, 85719, United States

No email / No phone

Status: Recruiting

Banner-University Medical Center Tucson Campus

Tucson, Arizona, 85719, United States

No email / No phone

Status: Recruiting

Banner-University Medical Center Tucson Campus

Tucson, Arizona, 85704, United States

No email / No phone

Status: Recruiting

UCLA Department of Medicine - Hematology & Oncology

Santa Monica, California, 90504, United States

No email / No phone

Status: Recruiting

UC Irvine Medical Center

Orange, California, 92868, United States

No email / No phone

Status: Recruiting

University of California, San Francisco | HDFCCC - Hematopoietic Malignancies

San Francisco, California, 94158, United States

No email / No phone

Status: Recruiting

Colorado West Healthcare, dba Grand Valley Oncology

Grand Junction, Colorado, 81505, United States

No email / No phone

Status: Recruiting

Colorado West Healthcare System, dba Community Hospital

Grand Junction, Colorado, 81505, United States

No email / No phone

Status: Recruiting

Danbury Hospital

Danbury, Connecticut, 06810, United States

No email / No phone

Status: Recruiting

The Whittingham Cancer Center / Norwalk Hospital

Norwalk, Connecticut, 06856, United States

No email / No phone

Status: Recruiting

Georgetown University Medical Center

Washington, District of Columbia, 20007, United States

No email / No phone

Status: Recruiting

MedStar Georgetown University Hospital

Washington, District of Columbia, 20007, United States

No email / No phone

Status: Recruiting

Moffitt Cancer Center - International Plaza

Tampa, Florida, 33607, United States

No email / No phone

Status: Recruiting

H. Lee Moffitt Cancer Center and Research Institute

Tampa, Florida, 33612, United States

No email / No phone

Status: Recruiting

Moffitt Cancer Center - McKinley Campus

Tampa, Florida, 33612, United States

No email / No phone

Status: Recruiting

Moffitt McKinley Hospital

Tampa, Florida, 33612, United States

No email / No phone

Status: Recruiting

Moffitt Cancer Center at Wesley Chapel

Wesley Chapel, Florida, 33544, United States

No email / No phone

Status: Recruiting

Georgia Cancer Specialists - Marietta

Marietta, Georgia, 30060, United States

No email / No phone

Status: Recruiting

Georgia Cancer Specialists - Athens

Athens, Georgia, 30606, United States

No email / No phone

Status: Recruiting

Georgia Cancer Specialists - Annex

Atlanta, Georgia, 30341, United States

No email / No phone

Status: Recruiting

Atlanta Cancer Care - Atlanta

Atlanta, Georgia, 30342, United States

No email / No phone

Status: Recruiting

Georgia Cancer Specialists-Northside

Atlanta, Georgia, 30342, United States

No email / No phone

Status: Recruiting

Northside Hospital, Inc.- Central Research Department

Atlanta, Georgia, 30342, United States

No email / No phone

Status: Recruiting

Northside Hospital

Atlanta, Georgia, 30342, United States

No email / No phone

Status: Recruiting

Georgia Cancer Specialists - Blairsville

Blairsville, Georgia, 30512, United States

No email / No phone

Status: Recruiting

Georgia Cancer Specialists - Canton

Canton, Georgia, 30115, United States

No email / No phone

Status: Recruiting

Atlanta Cancer Care - Cumming

Cumming, Georgia, 30041, United States

No email / No phone

Status: Recruiting

Georgia Cancer Specialists - Cumming

Cumming, Georgia, 30041, United States

No email / No phone

Status: Recruiting

Georgia Cancer Specialists - Decatur

Decatur, Georgia, 30033, United States

No email / No phone

Status: Recruiting

Suburban Hematology-Oncology Associates - Duluth

Duluth, Georgia, 30096, United States

No email / No phone

Status: Recruiting

Suburban Hematology-Oncology Associates- Lawrenceville

Lawrenceville, Georgia, 30046, United States

No email / No phone

Status: Recruiting

Georgia Cancer Specialists - Macon

Macon, Georgia, 31217, United States

No email / No phone

Status: Recruiting

Memorial Hospital

Shiloh, Illinois, 62269, United States

No email / No phone

Status: Recruiting

Siteman Cancer Center - Shiloh

Shiloh, Illinois, 62269, United States

No email / No phone

Status: Recruiting

Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States

No email / No phone

Status: Recruiting

Massachusetts General Hospital.

Boston, Massachusetts, 02114, United States

No email / No phone

Status: Recruiting

Brigham and Women's Hospital

Boston, Massachusetts, 02215, United States

No email / No phone

Status: Recruiting

Dana Farber Cancer Institute- Chestnut Hill

Newton, Massachusetts, 02459, United States

No email / No phone

Status: Recruiting

Barnes-Jewish Hospital

Saint Louis, Missouri, 63110, United States

No email / No phone

Status: Recruiting

Siteman Cancer Center - St Peters

Saint Peters, Missouri, 63376, United States

No email / No phone

Status: Recruiting

Siteman Cancer Center - South County

Saint Louis, Missouri, 63129, United States

No email / No phone

Status: Recruiting

Washington University School of Medicine - Siteman Cancer Center

Saint Louis, Missouri, 63110, United States

No email / No phone

Status: Recruiting

Washington University in St Louis.

Saint Louis, Missouri, 63110, United States

No email / No phone

Status: Recruiting

St Lukes Hospital

Kansas City, Missouri, 64111, United States

No email / No phone

Status: Recruiting

Saint Luke's Hospital Investigational Pharmacy

Kansas City, Missouri, 64111, United States

No email / No phone

Status: Recruiting

Saint Luke's Cancer Institute LLC

Kansas City, Missouri, 64111, United States

No email / No phone

Status: Recruiting

Siteman Cancer Center - North County

Florissant, Missouri, 63031, United States

No email / No phone

Status: Recruiting

Siteman Cancer Center - West County

Creve Coeur, Missouri, 63141, United States

No email / No phone

Status: Recruiting

Renown Regional Medical Center

Reno, Nevada, 89502, United States

No email / No phone

Status: Recruiting

San Juan Oncology Associates

Farmington, New Mexico, 87401, United States

No email / No phone

Status: TERMINATED

Memorial Sloan Kettering Cancer Center - Main Hospital

New York, New York, 10065, United States

No email / No phone

Status: Recruiting

Zangmeister Cancer Center

Columbus, Ohio, 43219, United States

No email / No phone

Status: Recruiting

Saint Francis Hospital / Bon Secours - South Carolina

Greenville, South Carolina, 29607, United States

No email / No phone

Status: Recruiting

Tennessee Oncology-Nashville/Sarah Cannon Research Institute

Nashville, Tennessee, 37203, United States

No email / No phone

Status: Recruiting

Sarah Cannon Research Institute - Pharmacy

Nashville, Tennessee, 37203, United States

No email / No phone

Status: Recruiting

SCRI Oncology Partners

Nashville, Tennessee, 37203, United States

No email / No phone

Status: Recruiting

University of Texas Southwestern Medical Center Simmons Cancer Center - Richardson/Plano

Richardson, Texas, 75080, United States

No email / No phone

Status: Recruiting

Parkland Health and Hospital System

Dallas, Texas, 75235, United States

No email / No phone

Status: Recruiting

University of Texas Southwestern Medical Center - Simmons Cancer Center

Dallas, Texas, 75235, United States

No email / No phone

Status: Recruiting

University of Texas Southwestern Medical Center-Simmons Cancer Center Pharmacy

Dallas, Texas, 75235, United States

No email / No phone

Status: Recruiting

University of Texas Southwestern Medical Center Simmons Cancer Center - Redbird

Dallas, Texas, 75237, United States

No email / No phone

Status: Recruiting

University of Texas Southwestern Medical Center Clinical Lab-Zale Lipshy University Hospital

Dallas, Texas, 75390, United States

No email / No phone

Status: Recruiting

University of Texas Southwestern Medical Center-William P. Clements Jr. University Hospital

Dallas, Texas, 75390, United States

No email / No phone

Status: Recruiting

University of Texas Southwestern Medical Center

Dallas, Texas, 75390, United States

No email / No phone

Status: Recruiting

University of Texas Southwestern Simmons Cancer Center - Fort Worth

Fort Worth, Texas, 76104, United States

No email / No phone

Status: Recruiting

Harborview Medical Center

Seattle, Washington, 98104, United States

No email / No phone

Status: Recruiting

University of Washington Medical Center

Seattle, Washington, 98195, United States

No email / No phone

Status: Recruiting

Fred Hutchinson Cancer Center / Seattle Cancer Care Alliance / University of Washington

Seattle, Washington, 98109, United States

No email / No phone

Status: Recruiting

Carbone Cancer Center / University of Wisconsin

Madison, Wisconsin, 53792, United States

No email / No phone

Status: Recruiting

University of Wisconsin Carbone Cancer Center - Eastpark Medical Center

Madison, Wisconsin, 53718, United States

No email / No phone

Status: Recruiting

A Phase 1b/2 Open-Label Study of Disitamab Vedotin in Combination With Other Anticancer Therapies in Solid Tumors

Trial Details

Show Summary from Sponsor

More details:

Investigational Drug AI Analysis

Show for: disitamab vedotin (RC48, Aidixi)

Clinical Efficacy and Safety

Sources:

HealthScout AI Analysis

Eligibility

Show Criteria

Sites (123)

Slade Health

Slade Pharmacy Frankston

Peninsula & South Eastern Hematology and Oncology Group (PASO)

Peninsula & South Eastern Hematology and Oncology Group (PASO)

BC Cancer Kelowna.

University Health Network, Princess Margaret Hospital

Ottawa Hospital Cancer Centre

Sunnybrook Health Sciences Centre

Universitatsklinikum Essen

Universitatsklinikum Heidelberg

Klinikums rechts der Isar der TU München

A.O.U. Federico II

Azienda Ospedaliera Universitaria (AOU) Federico II

Istituto Nazionale Tumori IRCCS Fondazione G. Pascale.

Istituto Europeo di Oncologia

Niguarda Ca' Granda Hospital

Humanitas Istituto Clinico Catanese

Azienda Ospedaliera Universitaria Integrata di Verona.

A.O.U. Federico II- U.O.C. Diagnostica per lmmagini e Radioterapia

Dong-A University Hospital

National Cancer Center

Chungbuk National University Hospital

Gachon University Gil Medical Center

Seoul National University Bundang Hospital

Korea University Anam Hospital

Samsung Medical Center

Seoul National University Hospital

Severance Hospital Yonsei University Health System

St. Vincent's Hospital, The Catholic University of Korea

Quirén Salud Barcelona

Hospital Clinico Universitario de Valencia

Ecg Medica Sl

START Madrid-CIOCC_Hospital HM Sanchinarro

Farmacia-Ensayos. Planta S - Hospital Universitario HM Sanchinarro-CIOCC-START Madrid

L'Institut Catala d'Oncologia.

Grupo Hospitalario QuironSalud

Hospital Universitario de Basurto

CETIR Grup Medic

Hospital Universitari Vall d´Hebron

National Cheng Kung University Hospital

National Taiwan University Hospital

National Taiwan University Hospital

National Taiwan University Cancer Center

National Cheng Kung University Hospital

The Royal Marsden Hospital

The Royal Marsden NHS Foundation Trust

St Bartholomew's Hospital

The Royal Marsden Hospital

The Royal Marsden NHS Foundation Trust (RM)

The Christie NHS Foundation Trust

The University of Arizona Cancer Center-Main

University of Arizona Cancer Center - North Campus

The University of Arizona Cancer Center-North Campus Pharmacy, Attn: Kelly Myrdal

Banner-University Medical Center Tucson

Banner-University Medical Center Tucson Campus

Banner-University Medical Center Tucson Campus

UCLA Department of Medicine - Hematology & Oncology

UC Irvine Medical Center

University of California, San Francisco | HDFCCC - Hematopoietic Malignancies

Colorado West Healthcare, dba Grand Valley Oncology

Colorado West Healthcare System, dba Community Hospital

Danbury Hospital

The Whittingham Cancer Center / Norwalk Hospital

Georgetown University Medical Center

MedStar Georgetown University Hospital

Moffitt Cancer Center - International Plaza

H. Lee Moffitt Cancer Center and Research Institute

Moffitt Cancer Center - McKinley Campus